Seeking Alpha

Colfax Capital is distinctly unimpressed by Oncothyreons (ONTY) development deal with Array....

Colfax Capital is distinctly unimpressed by Oncothyreons (ONTY) development deal with Array. "What a lousy company," Colax tweets. "Now inlicensing other compounds from ARRY while they inlicensed a Bcl last year that is collecting dust." The market is yet to pass its judgement.
Comments (1)
  • ed naples
    , contributor
    Comments (5) | Send Message
     
    Is Colfax Capital Shorting Onty?
    30 May 2013, 03:59 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs